Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a ...

Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a ...

Within the baricitinib group, patients experienced a mean Vitiligo Area Scoring Index score change of 44.8% from baseline to week 36. In contrast, the placebo group saw a 9.2% change. The Janus ...

Baricitinib can effectively treat polymyalgia rheumatica (PMR) without the use of oral glucocorticoids, according to results from a small, randomized, double-blind, placebo-controlled study.

The researchers then used baricitinib, a medication that selectively blocks the specific inflammatory pathways of lichen planus, to treat patients in the study. Cytokines are small proteins that ...

Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles. Breakdown of immune privilege in hair follicles leads to ...

The trials highlighted the potential of baricitinib as a viable treatment ... a growing understanding of the JAK/STAT signaling pathways involved in alopecia areata, which has led to the ...

Baricitinib, a Janus kinase (JAK) inhibitor, combined with narrowband ultraviolet B (UVB) phototherapy, reduced disease activity and improved repigmentation and quality of life in adults with ...

For the last year, he had been treated for atopic dermatitis with the Janus kinase (JAK) inhibitor baricitinib, which blocks the type I interferon signaling pathway, at a dose of 4 mg/day.